564 related articles for article (PubMed ID: 17848653)
1. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
Singh S; Loke YK; Furberg CD
JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Dahabreh IJ; Economopoulos K
Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
[TBL] [Abstract][Full Text] [Related]
3. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
Stone JC; Furuya-Kanamori L; Barendregt JJ; Doi SA
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):223-7. PubMed ID: 25515780
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
Lincoff AM; Wolski K; Nicholls SJ; Nissen SE
JAMA; 2007 Sep; 298(10):1180-8. PubMed ID: 17848652
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
Nissen SE; Wolski K
Arch Intern Med; 2010 Jul; 170(14):1191-1201. PubMed ID: 20656674
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159
[TBL] [Abstract][Full Text] [Related]
7. [Rosiglitazone: no increase in cardiovascular mortality].
Jazet IM; Meinders AE
Ned Tijdschr Geneeskd; 2009; 153():A942. PubMed ID: 19930745
[TBL] [Abstract][Full Text] [Related]
8. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
10. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
[TBL] [Abstract][Full Text] [Related]
12. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Nissen SE; Wolski K
N Engl J Med; 2007 Jun; 356(24):2457-71. PubMed ID: 17517853
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
Lipscombe LL; Gomes T; Lévesque LE; Hux JE; Juurlink DN; Alter DA
JAMA; 2007 Dec; 298(22):2634-43. PubMed ID: 18073359
[TBL] [Abstract][Full Text] [Related]
14. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk of rosiglitazone: another perspective.
Waksman JC
J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
[TBL] [Abstract][Full Text] [Related]
16. Long-term risk of rosiglitazone on cardiovascular events - a systematic review and meta-analysis.
Cheng D; Gao H; Li W
Endokrynol Pol; 2018; 69(4):381-394. PubMed ID: 29952413
[TBL] [Abstract][Full Text] [Related]
17. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
[TBL] [Abstract][Full Text] [Related]
18. The safety of rosiglitazone in the treatment of type 2 diabetes.
Singh S; Loke YK
Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
[TBL] [Abstract][Full Text] [Related]
19. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
Wallach JD; Wang K; Zhang AD; Cheng D; Grossetta Nardini HK; Lin H; Bracken MB; Desai M; Krumholz HM; Ross JS
BMJ; 2020 Feb; 368():l7078. PubMed ID: 32024657
[TBL] [Abstract][Full Text] [Related]
20. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis.
Singh S; Loke YK; Furberg CD
Thorax; 2011 May; 66(5):383-8. PubMed ID: 21325145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
